Quality of life evaluation by the EORTC QLQ-C30 questionnaire in patients treated with hormonal treatment in Italy. A QuABIOS group study

Domenico Prezioso, Riccardo Bartoletti, Massimo Cecchi, Virgilio Cicalese, Sergio Cosciani Cunico, Rocco Damiano, Antonello De Lisa, Nicola Franzolin, Bruno Frea, Giorgio Guazzoni, Ettore Mearini, Giuseppe Morgia, Giovanni Muzzonigro, Gaetano Oliva, Fausto Orestano, Arcangelo Pagliarulo, Giovanni L. Pappagallo, Paolo Parma, Massimo Perachino, Paolo PompaFrancesco Rocco, Filiberto Zattoni

Research output: Contribution to journalArticle


Objectives: An observational study was planned by the QwABIOS group, to survey the hormonal treatment administered to prostate cancer patients in Italy within a time win dow of 12 months. We report here a prospective quality of life (QOL) evaluation over time and by hormonal treatment modalities. Methods: Patients with diagnosis of prostate cancer and treated with hormonal therapy were eligible for thh study. The EORTC QLQ-C30 v.3 questionnaire was administered at enrol ment, after 6 months and after 12 months from enrolment. Results: 587 patients were enrolled by 33 urological centers. When 1518 vuits were considered together independently of time, antiandrogen monotherapy was associated with a significantly bet ter QOL than LHRH-analogue containing treatment modalities in almost all functional scales; cyproterone acetate demonstrated a better physical function and general health status than bica lutamide. When QOL was analyzed in a prospective 12-month window, a worsening of physical function and general health status was observed; notwithstanding, antiandrogens remained signif icantly associated to a better QOL than LHRH-analogue therapies also o\er time: a favourable physical function and general health status appeared again to be related to cyproterone acetate than bicalutamide. Conclusions: Androgen deprivation therapy is associated with decline in QOL, particularly in the domains of physical function, energy, and general health status. This survey demonstrated that antiandrogens had a better QOL profile than LHRH-analogue containing therapies; furthermore, a more favourable tolerability for cyproterone acetate as compared to bicalutamide is suggested.

Original languageEnglish
Pages (from-to)99-103
Number of pages5
JournalArchivio Italiano di Urologia e Andrologia
Issue number3
Publication statusPublished - Sep 2007


  • Antiandrogens
  • Hormonal treatment
  • LHRH-agonists
  • Prostate cancer
  • Quality of life

ASJC Scopus subject areas

  • Nephrology
  • Urology

Fingerprint Dive into the research topics of 'Quality of life evaluation by the EORTC QLQ-C30 questionnaire in patients treated with hormonal treatment in Italy. A QuABIOS group study'. Together they form a unique fingerprint.

Cite this